Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Assets: 2019-2025

Historic Assets for Burning Rock Biotech (BNR) over the last 4 years, with Sep 2025 value amounting to $114.1 million.

  • Burning Rock Biotech's Assets fell 18.70% to $114.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.1 million, marking a year-over-year decrease of 18.70%. This contributed to the annual value of $121.3 million for FY2024, which is 17.20% down from last year.
  • Burning Rock Biotech's Assets amounted to $114.1 million in Q3 2025, which was down 86.65% from $854.7 million recorded in Q1 2025.
  • Burning Rock Biotech's 5-year Assets high stood at $1.7 billion for Q3 2022, and its period low was $114.1 million during Q3 2025.
  • In the last 3 years, Burning Rock Biotech's Assets had a median value of $143.7 million in 2023 and averaged $556.9 million.
  • Its Assets has fluctuated over the past 5 years, first slumped by 90.38% in 2024, then soared by 526.58% in 2025.
  • Over the past 5 years, Burning Rock Biotech's Assets (Quarterly) stood at $357.6 million in 2021, then plummeted by 35.63% to $230.2 million in 2022, then plummeted by 36.36% to $146.5 million in 2023, then fell by 17.20% to $121.3 million in 2024, then fell by 18.70% to $114.1 million in 2025.
  • Its Assets was $114.1 million in Q3 2025, compared to $854.7 million in Q1 2025 and $121.3 million in Q4 2024.